Hep C - CROI: rapid response predicts success in HIV/HCV coinfected patients

CROI: rapid response predicts success in HIV/HCV coinfected patients
Aidsmap - Virological response to hepatitis C therapy after four weeks appears to predict who will have a successful response to a full course of treatment in HIV-positive people coinfected with hepatitis C genotypes 1 or 3, according to findings from two

Novartis And Idenix Seek European Approval Of Telbivudine (LDT600) For
Medical News Today - Novartis and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than